Results 201 to 210 of about 145,099 (296)

A Rare Case of Cutaneous Extramedullary Hematopoiesis in Chronic Myeloid Leukemia

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous extramedullary hematopoiesis (CEH) is a rare manifestation of extramedullary hematopoiesis (EMH), a process typically associated with fetal development or myeloproliferative neoplasms. EMH most commonly involves the spleen, liver, and lymph nodes, with CEH being exceedingly rare in chronic myeloid leukemia (CML).
Bennett Christie‐Nguyen   +5 more
wiley   +1 more source

Neutrophils unveiled in chronic lymphocytic leukemia. [PDF]

open access: yesFront Immunol
McManus S, Khare P, Bertilaccio MTS.
europepmc   +1 more source

The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives

open access: yesEuropean Journal of Haematology, EarlyView.
SAMHD1 regulates intracellular dNTP pools, influencing lentiviral transduction, gene therapy efficiency, and disease progression in pediatric hematological malignancies. Integrated bioinformatics and targeted strategies, including CRISPR and pharmacological inhibition, highlight its therapeutic potential.
Waseem Alzamzami
wiley   +1 more source

HAT‐PCR is non‐inferior to NGS when quantifying measurable residual disease for myeloma

open access: yes
British Journal of Haematology, EarlyView.
Elizabeth Hughes   +5 more
wiley   +1 more source

Postoperative Care and Management in Pediatric Hematology‐Oncology Patients

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Pediatric patients with hematologic and oncologic diseases often undergo surgical procedures as part of diagnosis and therapy. These include central venous catheter placements, tumor resections, lymph node and bone marrow biopsies, among others.
Shachi Srivatsa, Sara A. Mansfield
wiley   +1 more source

Transition Into Clinical Routine and Survival Outcomes of BCL2‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Within a dataset of the German CLL Study Group (GCLLSG) registry, 274 patients were allocated to a cohort with venetoclax and 888 to a cohort with BTKi (79 acalabrutinib, 809 ibrutinib), each as first administered targeted substance class within the documented treatment sequence.
Nadine Kutsch   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy